Ozden et al. [61] proved that BARD1β sensitizes colon cancer cells to poly PARP-1 inhibition even in an FL BARD1 background, thus suggesting that BARD1β may serve as a future biomarker for assessing the suitability of colon cancers for homologous recombination targeting with PARPi in the treatment of advanced colon cancer. This evidence concerns the gene PARP1 and malignant colon neoplasm.